A
Aaron E. Miller
Researcher at Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Publications - 43
Citations - 6117
Aaron E. Miller is an academic researcher from Corinne Goldsmith Dickinson Center for Multiple Sclerosis. The author has contributed to research in topics: Multiple sclerosis & Teriflunomide. The author has an hindex of 17, co-authored 43 publications receiving 4173 citations.
Papers
More filters
Journal ArticleDOI
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson,Brenda Banwell,Frederik Barkhof,Frederik Barkhof,William M. Carroll,Timothy Coetzee,Giancarlo Comi,Jorge Correale,Franz Fazekas,Massimo Filippi,Mark S. Freedman,Kazuo Fujihara,Steven L. Galetta,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Ruth Ann Marrie,Aaron E. Miller,David Miller,Xavier Montalban,Xavier Montalban,Ellen M. Mowry,Per Soelberg Sørensen,Mar Tintoré,Anthony Traboulsee,Maria Trojano,Bernard M. J. Uitdehaag,Sandra Vukusic,Sandra Vukusic,Emmanuelle Waubant,Brian G. Weinshenker,Stephen C. Reingold,Jeffrey A. Cohen +32 more
TL;DR: The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation.
Journal ArticleDOI
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
TL;DR: Although no treatment benefit was seen on the time to confirmed progression of disability, relapse- and MRI-related outcomes showed significant benefit with both dosing regimens tested, a result consistent with the outcomes of earlier clinical trials.
Journal ArticleDOI
Fatigue therapy in multiple sclerosis Results of a double‐blind, randomized, parallel trial of amantadine, pemoline, and placebo
Lauren B. Krupp,P. K. Coyle,Carol Doscher,Aaron E. Miller,Anne H. Cross,Lina Jandorf,June Halper,Britt A. Johnson,Linda Morgante,R. Grimson +9 more
TL;DR: Amantadine was significantly better than placebo in treating fatigue in MS patients, whereas pemoline was not, and the benefit of amantadines was not due to changes in sleep, depression, or neurologic disability.
Journal ArticleDOI
Selective decline in cellular immune response to varicella‐zoster in the elderly
TL;DR: The hypothesis that cellular immunity to varicella-zoster (VZ) viral antigens may be impaired in aged subjects is evaluated and it is found that the lymphocyte proliferation to VZ antigen was less in older asymptomatic individuals than in normal young controls.
Journal ArticleDOI
Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.
Fred D. Lublin,John N. Whitaker,B. H. Eidelman,Aaron E. Miller,Barry G. W. Arnason,Jack S. Burks +5 more
TL;DR: Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of exacerbations by one-third compared with placebo and limited new disease activity in the brain as evidenced by MRI.